Hamidreza Samadikhah

Hamidreza Samadikhah


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2023 in Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology
Verified
Journal Article
Closed access
Ghasem RashidianGhasem Rashidian
Ghasem Rashidian
RMRamin Mohammadi-Aloucheh
Ramin Mohammadi-Aloucheh
FHFarnaz Hosseinzadeh-Otaghvari
Farnaz Hosseinzadeh-Otaghvari
LCLatifeh Chupani
Latifeh Chupani
Vlastimil StejskalVlastimil Stejskal
Vlastimil Stejskal
Caterina FaggioCaterina Faggio
Caterina Faggio

20 August 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SASeyedeh Fatemeh Ahmadi
Seyedeh Fatemeh Ahmadi
SASeyed Shahriar Arab
Seyed Shahriar Arab
HSHamidreza Samadikhah
Hamidreza Samadikhah
Evidence indicates that the survivin protein is overexpressed in various types of cancer. Survivin belongs to the inhibitors of apoptosis proteins (IAPs) family, which plays a crucial role in preventing apoptosis and regulating the cell cycle. This protein has a multifaceted function in the cell cycle, particularly in regulating mitosis and cytokinesis. Survivin binds to XIAP, enhancing its stability, and interactively inhibiting caspase-9 activity. Additionally, survivin inhibits apoptosis by inactivating the Smac/DIABLO factor. In this study, we investigated the dual role of peptides in disrupting cell division and inducing apoptosis. Specifically, we designed anti-cancer peptides derived from the Borealin protein. Through single-point mutations, we developed several peptide variants and evaluated their efficacy using bioinformatics approaches, including molecular docking and molecular dynamics simulations. Based on these analyses, we identified P2 and P3 peptides as candidates with the highest binding affinities. Subsequently, the P3 was synthesized for experimental validation. By targeting key mechanisms involved in cancer cell survival and proliferation, P3 demonstrates significant potential as a novel anti-cancer agent with reduced side effects. These findings mark an important step forward in the development of more effective cancer therapies.

20 November 2025 in Scientific Reports
Verified
Journal Article
Open access
STSeyedeh Marzieh Taghavifar
Seyedeh Marzieh Taghavifar
SSSaba Sabbaghfarshi
Saba Sabbaghfarshi
HSHamidreza Samadikhah
Hamidreza Samadikhah
STSaeed Hesami Tackallou
Saeed Hesami Tackallou
SASeyedeh Fatemeh Ahmadi
Seyedeh Fatemeh Ahmadi
Apoptosis is a form of programmed cell death mediated by caspases and regulated through both intrinsic and extrinsic pathways. Many cancers evade apoptosis, resulting in uncontrolled cell survival and tumor progression. Inhibitor of apoptosis proteins (IAPs), including XIAP, cIAP1, cIAP2, ML-IAP (also known as Livin), Survivin, NAIP, ILP-2, and BRUCE (also known as Apollon), play crucial roles in suppressing apoptosis and promoting cancer cell survival. Survivin, which is overexpressed in various malignancies, inhibits caspase activity, protects XIAP from proteasomal degradation, and suppresses the intrinsic apoptotic pathway by inhibiting caspase-9 activity. In this study, we investigated the protective role of Survivin on other IAPs, particularly NAIP and cIAP1, using bioinformatics approaches such as homology modeling, molecular docking, and molecular dynamics simulations. Experimental validation in MCF-7 breast cancer cells demonstrated that a novel anticancer peptide, P3, disrupts the interaction between Survivin and IAPs. At 25 µM, P3 significantly enhanced caspase-8 and -9 (initiator) and caspases-3 and -7 (executioner) activities, activating pathways. These effects were confirmed by flow cytometry and DAPI/PI staining, showing increased apoptosis without necrosis. Our findings indicate P3 as a promising peptide-based therapy to overcome apoptosis resistance in breast cancer by targeting Survivin-IAP complexes, providing a foundation for novel anticancer strategies.